Genetics

Krystal Biotech announced a presentation of preclinical data assessing the in vitro and in vivo delivery of HSV-1 mediated KB103 at an upcoming conference.

Krystal Biotech (NASDAQ:KRYS) announced a presentation of preclinical data assessing the in vitro and in vivo delivery of HSV-1 mediated KB103 at an upcoming conference.
As quoted in the press release:

KB103 is Krystal’s lead product candidate, currently in preclinical development and seeks to use gene therapy to treat dystrophic epidermolysis bullosa, or DEB, an incurable skin blistering condition caused by a lack of collagen in the skin.  KB103 is a replication-defective, non-integrating viral vector that has been engineered employing Krystal’s STAR-D platform to deliver functional human COL7A1 genes directly to the patients’ dividing and non-dividing skin cells.

Click here to read the full press release.

Source: globenewswire.com

MARKETS

Markets
TSX19222.74-35.58
TSXV644.91-7.45
DOW30946.99-491.27
S&P 5003821.55-78.56
NASD11181.54-343.01
ASX6706.00+177.60

COMMODITIES

Commodities
Gold1819.88-3.55
Silver20.82-0.33
Copper3.76-0.01
Palladium1880.49+12.49
Platinum912.73+5.73
Oil111.62+2.05
Heating Oil4.10-0.01
Natural Gas6.51+0.01

DOWNLOAD FREE REPORTS

×